Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report

BACKGROUND: Chemoresistance generally develops in patients with advanced epithelial ovarian cancer, and the prognosis is still very poor, with an expected survival time of less than one year. For this population of individuals, there is currently no standard protocol for clinical benefit. CASE PRESE...

Descripción completa

Detalles Bibliográficos
Autores principales: Bian, Yuan, Guan, Ping, Li, Dan, Tan, Longjing, Pang, Haowen, Wen, Qinglian, Chen, Ping, Zhang, Zhenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797826/
https://www.ncbi.nlm.nih.gov/pubmed/36591480
http://dx.doi.org/10.3389/fonc.2022.1071383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797826/
https://www.ncbi.nlm.nih.gov/pubmed/36591480
http://dx.doi.org/10.3389/fonc.2022.1071383

Ejemplares similares